To The Moon
Home
News
TigerAI
Log In
Sign Up
chanch
+Follow
Posts · 46
Posts · 46
Following · 0
Following · 0
Followers · 0
Followers · 0
chanch
chanch
·
2022-03-28
Doesnt sound good
Piper Sandler Downgrades Beyond Meat Inc. to Underweight
Beyond Meat shares fell more than 4% in premarket trading after Piper Sandler downgraded Beyond Meat
Piper Sandler Downgrades Beyond Meat Inc. to Underweight
看
1.77K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
chanch
chanch
·
2022-03-14
No more booster jab pls!
Moderna Shares Soared Nearly 13% in Morning Trading
Moderna shares soared nearly 13% in morning trading.Moderna, Inc. (Nasdaq:MRNA), a biotechnology com
Moderna Shares Soared Nearly 13% in Morning Trading
看
1.98K
回复
Comment
点赞
5
编组 21备份 2
Share
Report
chanch
chanch
·
2021-09-19
Ok
Sorry, this post has been deleted
看
2.22K
回复
1
点赞
5
编组 21备份 2
Share
Report
chanch
chanch
·
2021-09-19
Ok
【老虎週刊】老虎社區一週十大精華文章
@老虎专刊：
嗨，虎友們好~這裏是老虎社區每週更新的欄目“老虎週刊”。 “老虎週刊”精選老虎社區虎友們一週精華寫作，希望對您的投資有所助力。 最好發現認識志同道合的虎友，一起投資一起成長。感謝虎友們支持，祝您投資順利！ 下面進入一週榜單： 《街頭智慧》：羅傑斯的反內卷投資人生 發佈者：@MidasMike 羅傑斯37歲便實現財富自由並激流勇退，歷時五年兩次自駕環遊世界成爲一個“投資騎士”，移居新加坡並用大量時間陪伴家人，在幾十年退休生活後，重倉新興市場的羅傑斯身家仍然高達3億美元。 在這個充滿競爭和焦慮的世界中，羅傑斯一直遵循着自己的節奏和直覺，他是一個反內卷的聰明投資者。 都給IPhone13測評，我給股王蘋果做測評！ 發佈者：@不二說價值 蘋果又開了一場發佈會，果粉們又毫不意外覺得不太滿意。 結合這個發佈會，我就趁熱打鐵，爲高達25000億美元的蘋果公司打一個分。 評分前所未有的高，也不是完美無缺，什麼價格介入更合適？ buy call錯了怎麼辦？上漲賺錢，下跌還能賺！美股期權最牛玩法 發佈者：
【老虎週刊】老虎社區一週十大精華文章
看
1.76K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
chanch
chanch
·
2021-08-29
Time to some challenge!
Sorry, this post has been deleted
看
2.27K
回复
3
点赞
4
编组 21备份 2
Share
Report
chanch
chanch
·
2021-08-10
Not a surprise!
3 Vaccine Stocks for the Next Decade
Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. W
3 Vaccine Stocks for the Next Decade
看
2.46K
回复
2
点赞
4
编组 21备份 2
Share
Report
chanch
chanch
·
2021-08-10
Oh wow!
Sorry, this post has been deleted
看
2.11K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
chanch
chanch
·
2021-08-05
Settling time
Coursera fell 3% after soaring 21% yesterday
(Aug 5) Coursera fell 3% after soaring 21% yesterday. the company have reported Q2 2021 financial r
Coursera fell 3% after soaring 21% yesterday
看
2.28K
回复
1
点赞
1
编组 21备份 2
Share
Report
chanch
chanch
·
2021-08-04
Roller coaster ride!
Sorry, this post has been deleted
看
2.02K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
chanch
chanch
·
2021-07-28
Wow
Sorry, this post has been deleted
看
1.64K
回复
Comment
点赞
7
编组 21备份 2
Share
Report
Load more
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3583728210057163","uuid":"3583728210057163","gmtCreate":1620638378496,"gmtModify":1621435601582,"name":"chanch","pinyin":"chanch","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":237,"tweetSize":46,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9010449813,"gmtCreate":1648458655734,"gmtModify":1676534340169,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Doesnt sound good","listText":"Doesnt sound good","text":"Doesnt sound good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9010449813","repostId":"1111470167","repostType":4,"repost":{"id":"1111470167","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648456625,"share":"https://ttm.financial/m/news/1111470167?lang=&edition=fundamental","pubTime":"2022-03-28 16:37","market":"us","language":"en","title":"Piper Sandler Downgrades Beyond Meat Inc. to Underweight","url":"https://stock-news.laohu8.com/highlight/detail?id=1111470167","media":"Tiger Newspress","summary":"Beyond Meat shares fell more than 4% in premarket trading after Piper Sandler downgraded Beyond Meat","content":"<html><head></head><body><p>Beyond Meat shares fell more than 4% in premarket trading after Piper Sandler downgraded Beyond Meat Inc. to Underweight.</p><p><img src=\"https://static.tigerbbs.com/762434a1e8bad27e5d22b82244a85ed0\" tg-width=\"843\" tg-height=\"618\" width=\"100%\" height=\"auto\"/></p><p>Piper Sandler analyst Michael Lavery downgraded Beyond Meat Inc. from Neutral to Underweight with a price target of $29.00 (from $50.00).</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Piper Sandler Downgrades Beyond Meat Inc. to Underweight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPiper Sandler Downgrades Beyond Meat Inc. to Underweight\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-28 16:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Beyond Meat shares fell more than 4% in premarket trading after Piper Sandler downgraded Beyond Meat Inc. to Underweight.</p><p><img src=\"https://static.tigerbbs.com/762434a1e8bad27e5d22b82244a85ed0\" tg-width=\"843\" tg-height=\"618\" width=\"100%\" height=\"auto\"/></p><p>Piper Sandler analyst Michael Lavery downgraded Beyond Meat Inc. from Neutral to Underweight with a price target of $29.00 (from $50.00).</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111470167","content_text":"Beyond Meat shares fell more than 4% in premarket trading after Piper Sandler downgraded Beyond Meat Inc. to Underweight.Piper Sandler analyst Michael Lavery downgraded Beyond Meat Inc. from Neutral to Underweight with a price target of $29.00 (from $50.00).","news_type":1,"symbols_score_info":{"BYND":0.9}},"isVote":1,"tweetType":1,"viewCount":1771,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9032949328,"gmtCreate":1647266968723,"gmtModify":1676534209870,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"No more booster jab pls! ","listText":"No more booster jab pls! ","text":"No more booster jab pls!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032949328","repostId":"1186570327","repostType":4,"repost":{"id":"1186570327","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1647265373,"share":"https://ttm.financial/m/news/1186570327?lang=&edition=fundamental","pubTime":"2022-03-14 21:42","market":"us","language":"en","title":"Moderna Shares Soared Nearly 13% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1186570327","media":"Tiger Newspress","summary":"Moderna shares soared nearly 13% in morning trading.Moderna, Inc. (Nasdaq:MRNA), a biotechnology com","content":"<html><head></head><body><p>Moderna shares soared nearly 13% in morning trading.</p><p>Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).</p><p>"Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been difficult to achieve. At Moderna, we believe that mRNA offers an opportunity to take a fresh approach to this challenge. With the launch of our second HIV vaccine trial, we are advancing our strategy to utilize multiple mRNA encoded native-like HIV trimers and leverage the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine," said Stephen Hoge, M.D., President of Moderna. "This study is another step in our fight against HIV, as well as other latent viruses such as our recently launched studies in CMV and EBV."</p><p>The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. The trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.</p><p>"It is gratifying to see that the experience with mRNA as a critical COVID-19 vaccine platform is now entering the HIV vaccine field," said Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network (HVTN) Leadership Operations Center, which is based at the Fred Hutchinson Cancer Research Center. "We are optimistic that this study will pave the way for continued approaches for using mRNA in HIV."</p><p>The trial is sponsored and funded by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH). The ClinicalTrials.gov identifier isNCT05217641. The envelope trimers being evaluated in this study were developed by William Schief, Ph.D., and colleagues. Dr. Schief is a professor at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center. Development of the native-like HIV trimers and manufacture of the HIV trimer mRNA vaccine (mRNA-1574) was funded by an NIAID (DAIDS) Consortium for HIV/AIDS Vaccine Development (CHAVD) grant to Scripps Research.</p><p>HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Worldwide, approximately 38 million are currently living with HIV, including approximately 1.2 million in the U.S.</p><p>Moderna is currently advancing two HIV preventative vaccine strategies based on germline targeting and immune-focusing approaches. In addition to this HIV trimer mRNA vaccine trial of mRNA-1574, Moderna is partnering in testing of HIV vaccine antigens mRNA-1644 and mRNA-1644v2-Core, being evaluated in aPhase I trialsponsored by IAVI and supported by the Bill & Melinda Gates Foundation.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Shares Soared Nearly 13% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Shares Soared Nearly 13% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-14 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Moderna shares soared nearly 13% in morning trading.</p><p>Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).</p><p>"Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been difficult to achieve. At Moderna, we believe that mRNA offers an opportunity to take a fresh approach to this challenge. With the launch of our second HIV vaccine trial, we are advancing our strategy to utilize multiple mRNA encoded native-like HIV trimers and leverage the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine," said Stephen Hoge, M.D., President of Moderna. "This study is another step in our fight against HIV, as well as other latent viruses such as our recently launched studies in CMV and EBV."</p><p>The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. The trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.</p><p>"It is gratifying to see that the experience with mRNA as a critical COVID-19 vaccine platform is now entering the HIV vaccine field," said Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network (HVTN) Leadership Operations Center, which is based at the Fred Hutchinson Cancer Research Center. "We are optimistic that this study will pave the way for continued approaches for using mRNA in HIV."</p><p>The trial is sponsored and funded by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH). The ClinicalTrials.gov identifier isNCT05217641. The envelope trimers being evaluated in this study were developed by William Schief, Ph.D., and colleagues. Dr. Schief is a professor at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center. Development of the native-like HIV trimers and manufacture of the HIV trimer mRNA vaccine (mRNA-1574) was funded by an NIAID (DAIDS) Consortium for HIV/AIDS Vaccine Development (CHAVD) grant to Scripps Research.</p><p>HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Worldwide, approximately 38 million are currently living with HIV, including approximately 1.2 million in the U.S.</p><p>Moderna is currently advancing two HIV preventative vaccine strategies based on germline targeting and immune-focusing approaches. In addition to this HIV trimer mRNA vaccine trial of mRNA-1574, Moderna is partnering in testing of HIV vaccine antigens mRNA-1644 and mRNA-1644v2-Core, being evaluated in aPhase I trialsponsored by IAVI and supported by the Bill & Melinda Gates Foundation.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186570327","content_text":"Moderna shares soared nearly 13% in morning trading.Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).\"Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been difficult to achieve. At Moderna, we believe that mRNA offers an opportunity to take a fresh approach to this challenge. With the launch of our second HIV vaccine trial, we are advancing our strategy to utilize multiple mRNA encoded native-like HIV trimers and leverage the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine,\" said Stephen Hoge, M.D., President of Moderna. \"This study is another step in our fight against HIV, as well as other latent viruses such as our recently launched studies in CMV and EBV.\"The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. The trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.\"It is gratifying to see that the experience with mRNA as a critical COVID-19 vaccine platform is now entering the HIV vaccine field,\" said Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network (HVTN) Leadership Operations Center, which is based at the Fred Hutchinson Cancer Research Center. \"We are optimistic that this study will pave the way for continued approaches for using mRNA in HIV.\"The trial is sponsored and funded by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH). The ClinicalTrials.gov identifier isNCT05217641. The envelope trimers being evaluated in this study were developed by William Schief, Ph.D., and colleagues. Dr. Schief is a professor at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center. Development of the native-like HIV trimers and manufacture of the HIV trimer mRNA vaccine (mRNA-1574) was funded by an NIAID (DAIDS) Consortium for HIV/AIDS Vaccine Development (CHAVD) grant to Scripps Research.HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Worldwide, approximately 38 million are currently living with HIV, including approximately 1.2 million in the U.S.Moderna is currently advancing two HIV preventative vaccine strategies based on germline targeting and immune-focusing approaches. In addition to this HIV trimer mRNA vaccine trial of mRNA-1574, Moderna is partnering in testing of HIV vaccine antigens mRNA-1644 and mRNA-1644v2-Core, being evaluated in aPhase I trialsponsored by IAVI and supported by the Bill & Melinda Gates Foundation.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1979,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887355448,"gmtCreate":1631981462884,"gmtModify":1676530682043,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/887355448","repostId":"2168757119","repostType":4,"isVote":1,"tweetType":1,"viewCount":2218,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887355513,"gmtCreate":1631981419632,"gmtModify":1676530682043,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887355513","repostId":"887339719","repostType":1,"repost":{"id":887339719,"gmtCreate":1631972463127,"gmtModify":1676530680476,"author":{"id":"35433028694349","authorId":"35433028694349","name":"老虎专刊","avatar":"https://static.laohu8.com/e0b93d50cf0df54ce7b1b746f78db36c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"35433028694349","idStr":"35433028694349"},"themes":[],"title":"【老虎週刊】老虎社區一週十大精華文章","htmlText":"嗨，虎友們好~這裏是老虎社區每週更新的欄目“老虎週刊”。 “老虎週刊”精選老虎社區虎友們一週精華寫作，希望對您的投資有所助力。 最好發現認識志同道合的虎友，一起投資一起成長。感謝虎友們支持，祝您投資順利！ 下面進入一週榜單： <a href=\"https://laohu8.com/TW/888195652\" target=\"_blank\">《街頭智慧》：羅傑斯的反內卷投資人生</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/3473459794537757\">@MidasMike</a> 羅傑斯37歲便實現財富自由並激流勇退，歷時五年兩次自駕環遊世界成爲一個“投資騎士”，移居新加坡並用大量時間陪伴家人，在幾十年退休生活後，重倉新興市場的羅傑斯身家仍然高達3億美元。 在這個充滿競爭和焦慮的世界中，羅傑斯一直遵循着自己的節奏和直覺，他是一個反內卷的聰明投資者。 <a href=\"https://laohu8.com/TW/885694539\" target=\"_blank\">都給IPhone13測評，我給股王蘋果做測評！</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/3545995761422355\">@不二說價值</a> 蘋果又開了一場發佈會，果粉們又毫不意外覺得不太滿意。 結合這個發佈會，我就趁熱打鐵，爲高達25000億美元的蘋果公司打一個分。 評分前所未有的高，也不是完美無缺，什麼價格介入更合適？ <a href=\"https://laohu8.com/TW/881508993\" target=\"_blank\">buy call錯了怎麼辦？上漲賺錢，下跌還能賺！美股期權最牛玩法</a> 發佈者：","listText":"嗨，虎友們好~這裏是老虎社區每週更新的欄目“老虎週刊”。 “老虎週刊”精選老虎社區虎友們一週精華寫作，希望對您的投資有所助力。 最好發現認識志同道合的虎友，一起投資一起成長。感謝虎友們支持，祝您投資順利！ 下面進入一週榜單： <a href=\"https://laohu8.com/TW/888195652\" target=\"_blank\">《街頭智慧》：羅傑斯的反內卷投資人生</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/3473459794537757\">@MidasMike</a> 羅傑斯37歲便實現財富自由並激流勇退，歷時五年兩次自駕環遊世界成爲一個“投資騎士”，移居新加坡並用大量時間陪伴家人，在幾十年退休生活後，重倉新興市場的羅傑斯身家仍然高達3億美元。 在這個充滿競爭和焦慮的世界中，羅傑斯一直遵循着自己的節奏和直覺，他是一個反內卷的聰明投資者。 <a href=\"https://laohu8.com/TW/885694539\" target=\"_blank\">都給IPhone13測評，我給股王蘋果做測評！</a> 發佈者：<a target=\"_blank\" href=\"https://laohu8.com/U/3545995761422355\">@不二說價值</a> 蘋果又開了一場發佈會，果粉們又毫不意外覺得不太滿意。 結合這個發佈會，我就趁熱打鐵，爲高達25000億美元的蘋果公司打一個分。 評分前所未有的高，也不是完美無缺，什麼價格介入更合適？ <a href=\"https://laohu8.com/TW/881508993\" target=\"_blank\">buy call錯了怎麼辦？上漲賺錢，下跌還能賺！美股期權最牛玩法</a> 發佈者：","text":"嗨，虎友們好~這裏是老虎社區每週更新的欄目“老虎週刊”。 “老虎週刊”精選老虎社區虎友們一週精華寫作，希望對您的投資有所助力。 最好發現認識志同道合的虎友，一起投資一起成長。感謝虎友們支持，祝您投資順利！ 下面進入一週榜單： 《街頭智慧》：羅傑斯的反內卷投資人生 發佈者：@MidasMike 羅傑斯37歲便實現財富自由並激流勇退，歷時五年兩次自駕環遊世界成爲一個“投資騎士”，移居新加坡並用大量時間陪伴家人，在幾十年退休生活後，重倉新興市場的羅傑斯身家仍然高達3億美元。 在這個充滿競爭和焦慮的世界中，羅傑斯一直遵循着自己的節奏和直覺，他是一個反內卷的聰明投資者。 都給IPhone13測評，我給股王蘋果做測評！ 發佈者：@不二說價值 蘋果又開了一場發佈會，果粉們又毫不意外覺得不太滿意。 結合這個發佈會，我就趁熱打鐵，爲高達25000億美元的蘋果公司打一個分。 評分前所未有的高，也不是完美無缺，什麼價格介入更合適？ buy call錯了怎麼辦？上漲賺錢，下跌還能賺！美股期權最牛玩法 發佈者：","images":[{"img":"https://static.tigerbbs.com/3d5e2fc85108344477e4c0796d4f7359","width":"1717","height":"924"},{"img":"https://static.tigerbbs.com/99f2c14a32d644799c78e85ffdbce509","width":"755","height":"429"},{"img":"https://static.tigerbbs.com/a05c777fdd742a2cdc135436ad862e92","width":"928","height":"619"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887339719","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":12,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1758,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813819894,"gmtCreate":1630167062418,"gmtModify":1676530237453,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Time to some challenge! ","listText":"Time to some challenge! ","text":"Time to some challenge!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/813819894","repostId":"2162907389","repostType":4,"isVote":1,"tweetType":1,"viewCount":2273,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896868203,"gmtCreate":1628569899302,"gmtModify":1703508301835,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Not a surprise! ","listText":"Not a surprise! ","text":"Not a surprise!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/896868203","repostId":"1181756731","repostType":4,"repost":{"id":"1181756731","kind":"news","pubTimestamp":1628563781,"share":"https://ttm.financial/m/news/1181756731?lang=&edition=fundamental","pubTime":"2021-08-10 10:49","market":"us","language":"en","title":"3 Vaccine Stocks for the Next Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1181756731","media":"The Motley Fool","summary":"Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. W","content":"<p><i><b>Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years?</b></i></p>\n<p>Over the last 18 months, COVID-19 has dominated the stock market in general, and vaccine stocks in particular. Companies and governments are trying to vaccinate as many people as possible to minimize the threat of this disease and maybe even eradicate it. That's the here and now, and any news can send vaccine stocks soaring, or crashing, overnight.</p>\n<p>It's hard to imagine what the vaccine stocks will look like 10 years from now. Will COVID-19 still be in the headlines? Or will it recede in importance? A group of Fool contributors suggest you might want to buy shares of <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>, <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> , and <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology, Inc.</a>. Here's why.</p>\n<h3><b>This vaccine superstar will continue to outperform</b></h3>\n<p><b>Patrick Bafuma</b> <b>(Moderna):</b> Talk about setting a high bar with your first drug to market. With $20 billion in advance purchase agreements for 2021, Moderna's COVID-19 vaccine, Spikevax, is set to rival Humira for the best-selling drug in the world in 2021. Not to be proved a fluke, in 2022 this vaccine giant also has $12 billion in advance purchase agreements and another $8 billion in options for Spikevax.</p>\n<p>If there is one thing COVID-19 has demonstrated, it is that this disease is resilient. With New York City set to implement vaccine passports for gyms and indoor dining, other destinations may not be far behind. And with some employers and higher education programs starting to require vaccinations, not to mention the inevitable need for boosters, I believe the demand for jabs of the company's product, which just generated $4.4 billion in second-quarter revenue, will likely remain high.</p>\n<p>We already knew the COVID-19 vaccine was a boon for Moderna. And its flu vaccine is expected to be on the market in 2023 -- a market worth $5 billion to $6 billion annually. And you probably already knew that the mRNA specialist was working toward having a combination flu/respiratory syncytial virus/COVID-19 vaccination. Maybe you even knew that the company's $2 billion to $5 billion cytomegalovirus vaccine candidate is close to entering phase 3 trials. What you may not have known about is CEO Stéphane Bancel's long-term investment in oncology vaccines.</p>\n<p>The company has two exciting cancer vaccines in a 50-50 partnership with <a href=\"https://laohu8.com/S/MRK\">Merck</a> that I am keeping an eye on. These vaccines work by providing patients with an injection of mRNA that gets the patient's immune system to recognize specific abnormalities that are the hallmark of cancerous cells and then get the patient's own immune system to attack the cancer.</p>\n<p>The most advanced product of this collaboration, a \"personal cancer vaccine\" for head and neck squamous cell carcinoma, is currently in phase 2 trials. Thus far in its earlier trials, the treatment has a 50% response rate, more improvements in tumor burden over time, and longer progression-free survival than current standards of care.</p>\n<p>The other Merck-partnered oncology vaccine, while only in phase 1 trials, has a massive addressable market. This one targets mutations within the KRAS gene, with alterations of KRAS present in more than 20% of human cancers. With Moderna's KRAS vaccine covering 80% to 90% of KRAS mutations with its vaccine, this has potential to be another multi-billion-dollar treatment for the company.</p>\n<p>Yes, Spikevax will continue to be the company's cash cow. However, with $12.2 billion in cash and investments, and generating over $4 billion in revenue a quarter, the company has plenty of cash to fuel its research and development pipeline. If we're looking for an innovative vaccine maker to boost the portfolio of healthcare investors for the next 10 years, Moderna has lots of firepower in its pipeline, street credibility, and plenty of cash to make it all happen.</p>\n<h3><b>A $7-billion-a-year opportunity</b></h3>\n<p><b>George Budwell</b> <b>(Pfizer):</b> Although vaccines have long been a steady source of revenue for multiple big pharmas, investors have historically ignored the value of this particular product category -- that is, until the COVID-19 pandemic hit. The core reason is that vaccines, by and large, tend to be modest revenue generators for their manufacturers, with a few glaring exceptions such as <b>GlaxoSmithKline</b>'s Shingrix and Pfizer's blockbuster Prevnar franchise.</p>\n<p>Another issue is that vaccines have proven to be extremely difficult to develop for some of the most common viral agents. Respiratory syncytial virus, for example, is a seasonal illness that reportedly results in a whopping 58,000 hospitalizations per year in children younger than 5 and 177,000 in people over the age of 65, according to the Centers for Disease Control and Prevention. Yet there are still no fully protective vaccines approved for this large unmet medical need -- despite multiple attempts to develop such a vaccine over the past 60-plus years. Wall Street analysts, in turn, believe that the first company to achieve this lofty goal could be awarded with a product capable of generating over $7 billion per year in sales.</p>\n<p>Which big pharma has the inside track at breaking into this enormous market? As things stand right now, Pfizer is arguably sitting in the catbird seat with its RSV candidate known as RSVpreF. The company recently rolled out exceedingly impressive results for the vaccine in a midstage challenge study in adults under the age of 50. Pfizer has thus decided to advance RSVpreF into a critical phase 3 trial in adults, which is set to kick off next month. Top-line results from this global phase 3 trial ought to be available sometime in the first quarter of 2022.</p>\n<p>If this highly anticipated trial does indeed hit the mark, the pharma titan would almost certainly have its next superstar vaccine product -- possibly making its stock a great buy for long-term investors.</p>\n<h3><b>\"A world without infectious disease\"</b></h3>\n<p><b>Taylor Carmichael</b> <b>(Vir Biotechnology):</b> Vir Bio's mission statement -- \"creating a world without infectious disease\" -- is kind of amazing. If the biotech succeeds in eliminating infectious disease from the planet, it will be the most valuable healthcare company in the world.</p>\n<p>While it's hugely ambitious, it's not impossible. After all, we've largely eliminated some viral diseases like polio and smallpox. And it was vaccines that did it. What Vir is attempting to do, as I understand it, is use the breakthroughs in genomic research to find one-and-done vaccines for diseases like COVID-19, hepatitis B, influenza, and HIV. The company actually has four platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA).</p>\n<p>We might ask why this vaccine company isn't a leader in COVID-19 vaccines. Vir Bio may or may not be in last place, but it's way back in the race. The company's vaccine, sotrovimab, is still in its<i>pre-clinical</i>phase. Meanwhile, the mRNA vaccines from Moderna and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> have been on the market for months. The <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> vaccine has suffered delays, but should be on the market soon. This is a remarkably quick pace, and shareholders of all three companies have been amply rewarded over the last 18 months.</p>\n<p><img src=\"https://static.tigerbbs.com/d0a1bd43968c51fecbafbb7569fc669f\" tg-width=\"720\" tg-height=\"500\" referrerpolicy=\"no-referrer\">NVAXDATA BY YCHARTS</p>\n<p>Compared to the 5,000% return of Novavax, or the 2,000% return of Moderna, or the 1,000% jump BioNTech investors have received, Vir's 200% gain is a little disappointing. (On the other hand, Vir shareholders did six times better than people who invested in an index fund.)</p>\n<p>The main reason Novavax, Moderna, and BioNTech have soared is that all three companies focused on the spike protein of the coronavirus. This has been incredibly successful, creating large numbers of antibodies. If a vaccine produces a large enough level of antibodies, it wards off the disease and keeps people from getting infected.</p>\n<p>What about the future, and all the mutating strains? Historically, the way vaccine companies dealt with mutation in the past, like with the flu, was to vaccinate people again and again. You vaccinate for the known strains and hope the drug will produce enough antibodies and T cells to ward off mutating strains as well. That's why both Novavax and Moderna are pursuing a flu/COVID-19 combo shot -- the plan is for people to take it every year.</p>\n<p>That plan might come to a crashing halt if Vir succeeds with its one-and-done vaccine. While Vir might seem too far back in the race to make any difference, the company has an ace up its sleeve. The Food and Drug Administration has given the company an Emergency Use Authorization to market sotrovimab not as a vaccine, but as a treatment for people who have already been infected with COVID-19. So investors will have real-world data about how the company's drug works.</p>\n<p>Of course the COVID-19 treatment market is vastly smaller than the vaccine market. But what makes Vir so interesting is the company's ultimate focus. Its mission is to eliminate infectious disease from the planet. Today, you might invest in Vir for its COVID-19 treatment. But what's really exciting are the vaccines the company hopes to introduce over the next decade. If Vir successfully removes one major illness from the world, investors will make a lot of money.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Vaccine Stocks for the Next Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Vaccine Stocks for the Next Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 10:49 GMT+8 <a href=https://www.fool.com/investing/2021/08/09/3-vaccine-stocks-for-the-next-decade/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years?\nOver the last 18 months, COVID-19 has dominated ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/09/3-vaccine-stocks-for-the-next-decade/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE","NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","VIR":"Vir Biotechnology, Inc.","MRK":"默沙东"},"source_url":"https://www.fool.com/investing/2021/08/09/3-vaccine-stocks-for-the-next-decade/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181756731","content_text":"Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years?\nOver the last 18 months, COVID-19 has dominated the stock market in general, and vaccine stocks in particular. Companies and governments are trying to vaccinate as many people as possible to minimize the threat of this disease and maybe even eradicate it. That's the here and now, and any news can send vaccine stocks soaring, or crashing, overnight.\nIt's hard to imagine what the vaccine stocks will look like 10 years from now. Will COVID-19 still be in the headlines? Or will it recede in importance? A group of Fool contributors suggest you might want to buy shares of Moderna, Inc., Pfizer , and Vir Biotechnology, Inc.. Here's why.\nThis vaccine superstar will continue to outperform\nPatrick Bafuma (Moderna): Talk about setting a high bar with your first drug to market. With $20 billion in advance purchase agreements for 2021, Moderna's COVID-19 vaccine, Spikevax, is set to rival Humira for the best-selling drug in the world in 2021. Not to be proved a fluke, in 2022 this vaccine giant also has $12 billion in advance purchase agreements and another $8 billion in options for Spikevax.\nIf there is one thing COVID-19 has demonstrated, it is that this disease is resilient. With New York City set to implement vaccine passports for gyms and indoor dining, other destinations may not be far behind. And with some employers and higher education programs starting to require vaccinations, not to mention the inevitable need for boosters, I believe the demand for jabs of the company's product, which just generated $4.4 billion in second-quarter revenue, will likely remain high.\nWe already knew the COVID-19 vaccine was a boon for Moderna. And its flu vaccine is expected to be on the market in 2023 -- a market worth $5 billion to $6 billion annually. And you probably already knew that the mRNA specialist was working toward having a combination flu/respiratory syncytial virus/COVID-19 vaccination. Maybe you even knew that the company's $2 billion to $5 billion cytomegalovirus vaccine candidate is close to entering phase 3 trials. What you may not have known about is CEO Stéphane Bancel's long-term investment in oncology vaccines.\nThe company has two exciting cancer vaccines in a 50-50 partnership with Merck that I am keeping an eye on. These vaccines work by providing patients with an injection of mRNA that gets the patient's immune system to recognize specific abnormalities that are the hallmark of cancerous cells and then get the patient's own immune system to attack the cancer.\nThe most advanced product of this collaboration, a \"personal cancer vaccine\" for head and neck squamous cell carcinoma, is currently in phase 2 trials. Thus far in its earlier trials, the treatment has a 50% response rate, more improvements in tumor burden over time, and longer progression-free survival than current standards of care.\nThe other Merck-partnered oncology vaccine, while only in phase 1 trials, has a massive addressable market. This one targets mutations within the KRAS gene, with alterations of KRAS present in more than 20% of human cancers. With Moderna's KRAS vaccine covering 80% to 90% of KRAS mutations with its vaccine, this has potential to be another multi-billion-dollar treatment for the company.\nYes, Spikevax will continue to be the company's cash cow. However, with $12.2 billion in cash and investments, and generating over $4 billion in revenue a quarter, the company has plenty of cash to fuel its research and development pipeline. If we're looking for an innovative vaccine maker to boost the portfolio of healthcare investors for the next 10 years, Moderna has lots of firepower in its pipeline, street credibility, and plenty of cash to make it all happen.\nA $7-billion-a-year opportunity\nGeorge Budwell (Pfizer): Although vaccines have long been a steady source of revenue for multiple big pharmas, investors have historically ignored the value of this particular product category -- that is, until the COVID-19 pandemic hit. The core reason is that vaccines, by and large, tend to be modest revenue generators for their manufacturers, with a few glaring exceptions such as GlaxoSmithKline's Shingrix and Pfizer's blockbuster Prevnar franchise.\nAnother issue is that vaccines have proven to be extremely difficult to develop for some of the most common viral agents. Respiratory syncytial virus, for example, is a seasonal illness that reportedly results in a whopping 58,000 hospitalizations per year in children younger than 5 and 177,000 in people over the age of 65, according to the Centers for Disease Control and Prevention. Yet there are still no fully protective vaccines approved for this large unmet medical need -- despite multiple attempts to develop such a vaccine over the past 60-plus years. Wall Street analysts, in turn, believe that the first company to achieve this lofty goal could be awarded with a product capable of generating over $7 billion per year in sales.\nWhich big pharma has the inside track at breaking into this enormous market? As things stand right now, Pfizer is arguably sitting in the catbird seat with its RSV candidate known as RSVpreF. The company recently rolled out exceedingly impressive results for the vaccine in a midstage challenge study in adults under the age of 50. Pfizer has thus decided to advance RSVpreF into a critical phase 3 trial in adults, which is set to kick off next month. Top-line results from this global phase 3 trial ought to be available sometime in the first quarter of 2022.\nIf this highly anticipated trial does indeed hit the mark, the pharma titan would almost certainly have its next superstar vaccine product -- possibly making its stock a great buy for long-term investors.\n\"A world without infectious disease\"\nTaylor Carmichael (Vir Biotechnology): Vir Bio's mission statement -- \"creating a world without infectious disease\" -- is kind of amazing. If the biotech succeeds in eliminating infectious disease from the planet, it will be the most valuable healthcare company in the world.\nWhile it's hugely ambitious, it's not impossible. After all, we've largely eliminated some viral diseases like polio and smallpox. And it was vaccines that did it. What Vir is attempting to do, as I understand it, is use the breakthroughs in genomic research to find one-and-done vaccines for diseases like COVID-19, hepatitis B, influenza, and HIV. The company actually has four platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA).\nWe might ask why this vaccine company isn't a leader in COVID-19 vaccines. Vir Bio may or may not be in last place, but it's way back in the race. The company's vaccine, sotrovimab, is still in itspre-clinicalphase. Meanwhile, the mRNA vaccines from Moderna and BioNTech SE have been on the market for months. The Novavax vaccine has suffered delays, but should be on the market soon. This is a remarkably quick pace, and shareholders of all three companies have been amply rewarded over the last 18 months.\nNVAXDATA BY YCHARTS\nCompared to the 5,000% return of Novavax, or the 2,000% return of Moderna, or the 1,000% jump BioNTech investors have received, Vir's 200% gain is a little disappointing. (On the other hand, Vir shareholders did six times better than people who invested in an index fund.)\nThe main reason Novavax, Moderna, and BioNTech have soared is that all three companies focused on the spike protein of the coronavirus. This has been incredibly successful, creating large numbers of antibodies. If a vaccine produces a large enough level of antibodies, it wards off the disease and keeps people from getting infected.\nWhat about the future, and all the mutating strains? Historically, the way vaccine companies dealt with mutation in the past, like with the flu, was to vaccinate people again and again. You vaccinate for the known strains and hope the drug will produce enough antibodies and T cells to ward off mutating strains as well. That's why both Novavax and Moderna are pursuing a flu/COVID-19 combo shot -- the plan is for people to take it every year.\nThat plan might come to a crashing halt if Vir succeeds with its one-and-done vaccine. While Vir might seem too far back in the race to make any difference, the company has an ace up its sleeve. The Food and Drug Administration has given the company an Emergency Use Authorization to market sotrovimab not as a vaccine, but as a treatment for people who have already been infected with COVID-19. So investors will have real-world data about how the company's drug works.\nOf course the COVID-19 treatment market is vastly smaller than the vaccine market. But what makes Vir so interesting is the company's ultimate focus. Its mission is to eliminate infectious disease from the planet. Today, you might invest in Vir for its COVID-19 treatment. But what's really exciting are the vaccines the company hopes to introduce over the next decade. If Vir successfully removes one major illness from the world, investors will make a lot of money.","news_type":1,"symbols_score_info":{"VIR":0.9,"PFE":0.9,"NVAX":0.9,"MRK":0.9,"MRNA":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":2456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896868980,"gmtCreate":1628569860940,"gmtModify":1703508300862,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Oh wow! ","listText":"Oh wow! ","text":"Oh wow!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896868980","repostId":"1186259544","repostType":4,"isVote":1,"tweetType":1,"viewCount":2105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899837205,"gmtCreate":1628172944607,"gmtModify":1703502574255,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Settling time ","listText":"Settling time ","text":"Settling time","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899837205","repostId":"1132594719","repostType":4,"repost":{"id":"1132594719","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628171470,"share":"https://ttm.financial/m/news/1132594719?lang=&edition=fundamental","pubTime":"2021-08-05 21:51","market":"us","language":"en","title":"Coursera fell 3% after soaring 21% yesterday","url":"https://stock-news.laohu8.com/highlight/detail?id=1132594719","media":"Tiger Newspress","summary":"(Aug 5) Coursera fell 3% after soaring 21% yesterday. \nthe company have reported Q2 2021 financial r","content":"<p>(Aug 5) Coursera fell 3% after soaring 21% yesterday. </p>\n<p><img src=\"https://static.tigerbbs.com/b4c30f620d3324d65c0c18c0207d5830\" tg-width=\"1129\" tg-height=\"653\" referrerpolicy=\"no-referrer\">the company have reported Q2 2021 financial results that look \"mixed\" in the extreme yesterday .</p>\n<p>On the one hand, Coursera blew away analyst targets for Q2 revenue, producing $102.1 million where Wall Street had expected only $91.5 million. On the other hand, though, Coursera appears to have missed analyst predictions on profit entirely. According to a writeup fromTheFly.comthis morning, instead of the predicted $0.11-per-share loss, Coursera lost $0.38 per share.</p>\n<p>Wait, what? Coursera lost three times as much money as it was \"supposed\" to, and its stock is going up? At first glance, it certainly does look that way. So let me unravel the mystery for you.</p>\n<p>When analysts make earnings estimates, they most often refer not to earnings calculated according to generally accepted accounting principles (GAAP) but rather topro formaearnings. And this fact can create some confusion among investors around earnings time as to whether a company \"beat\" or \"missed\" earnings.</p>\n<p>So in the case of Coursera, analysts forecast that the company would lose $0.11 per share<i>pro forma.</i>But the earnings number TheFly and other financial outlets refer to -- the $0.38-per-share loss -- was the company's<i>GAAP</i>loss. If you back out all the one-time charges (or what analysts consider one-time charges) from Coursera's results, though, the company's<i>pro forma</i>loss for the quarter was only $0.05 per share.</p>\n<p>Or in other words, comparing apples to apples, this was not an earnings \"miss,\" but an earnings \"beat.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coursera fell 3% after soaring 21% yesterday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoursera fell 3% after soaring 21% yesterday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-05 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Aug 5) Coursera fell 3% after soaring 21% yesterday. </p>\n<p><img src=\"https://static.tigerbbs.com/b4c30f620d3324d65c0c18c0207d5830\" tg-width=\"1129\" tg-height=\"653\" referrerpolicy=\"no-referrer\">the company have reported Q2 2021 financial results that look \"mixed\" in the extreme yesterday .</p>\n<p>On the one hand, Coursera blew away analyst targets for Q2 revenue, producing $102.1 million where Wall Street had expected only $91.5 million. On the other hand, though, Coursera appears to have missed analyst predictions on profit entirely. According to a writeup fromTheFly.comthis morning, instead of the predicted $0.11-per-share loss, Coursera lost $0.38 per share.</p>\n<p>Wait, what? Coursera lost three times as much money as it was \"supposed\" to, and its stock is going up? At first glance, it certainly does look that way. So let me unravel the mystery for you.</p>\n<p>When analysts make earnings estimates, they most often refer not to earnings calculated according to generally accepted accounting principles (GAAP) but rather topro formaearnings. And this fact can create some confusion among investors around earnings time as to whether a company \"beat\" or \"missed\" earnings.</p>\n<p>So in the case of Coursera, analysts forecast that the company would lose $0.11 per share<i>pro forma.</i>But the earnings number TheFly and other financial outlets refer to -- the $0.38-per-share loss -- was the company's<i>GAAP</i>loss. If you back out all the one-time charges (or what analysts consider one-time charges) from Coursera's results, though, the company's<i>pro forma</i>loss for the quarter was only $0.05 per share.</p>\n<p>Or in other words, comparing apples to apples, this was not an earnings \"miss,\" but an earnings \"beat.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COUR":"Coursera, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132594719","content_text":"(Aug 5) Coursera fell 3% after soaring 21% yesterday. \nthe company have reported Q2 2021 financial results that look \"mixed\" in the extreme yesterday .\nOn the one hand, Coursera blew away analyst targets for Q2 revenue, producing $102.1 million where Wall Street had expected only $91.5 million. On the other hand, though, Coursera appears to have missed analyst predictions on profit entirely. According to a writeup fromTheFly.comthis morning, instead of the predicted $0.11-per-share loss, Coursera lost $0.38 per share.\nWait, what? Coursera lost three times as much money as it was \"supposed\" to, and its stock is going up? At first glance, it certainly does look that way. So let me unravel the mystery for you.\nWhen analysts make earnings estimates, they most often refer not to earnings calculated according to generally accepted accounting principles (GAAP) but rather topro formaearnings. And this fact can create some confusion among investors around earnings time as to whether a company \"beat\" or \"missed\" earnings.\nSo in the case of Coursera, analysts forecast that the company would lose $0.11 per sharepro forma.But the earnings number TheFly and other financial outlets refer to -- the $0.38-per-share loss -- was the company'sGAAPloss. If you back out all the one-time charges (or what analysts consider one-time charges) from Coursera's results, though, the company'spro formaloss for the quarter was only $0.05 per share.\nOr in other words, comparing apples to apples, this was not an earnings \"miss,\" but an earnings \"beat.\"","news_type":1,"symbols_score_info":{"COUR":0.9}},"isVote":1,"tweetType":1,"viewCount":2283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890077515,"gmtCreate":1628071841737,"gmtModify":1703500663435,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Roller coaster ride! ","listText":"Roller coaster ride! ","text":"Roller coaster ride!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890077515","repostId":"1120792298","repostType":4,"isVote":1,"tweetType":1,"viewCount":2019,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801981924,"gmtCreate":1627479524768,"gmtModify":1703490752094,"author":{"id":"3583728210057163","authorId":"3583728210057163","name":"chanch","avatar":"https://static.tigerbbs.com/9f55a76964675aa242f7e754a1396b78","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583728210057163","idStr":"3583728210057163"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801981924","repostId":"1102507343","repostType":4,"isVote":1,"tweetType":1,"viewCount":1644,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}